0
0 (0%)
Mesoblast Ltd [MEOBF]
Source:
Company Overview
Mesoblast is developing rexlemestrocel-L to fill the treatment gap for chronic heart failure (CHF). Patients with CHF continue to represent high unmet medical need despite recent advances in new therapeutic agents for chronic heart failure.
Country | United States |
Headquarters | melbourne |
Phone Number | 61(3) 9639 6036 |
Industry | manufacturing |
CEO | Silviu Itescu |
Website | www.mesoblast.com |